1. Mccracken M, Olsen M, Chen JRMS, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence mortality and associated risk factors among Asian and Americans of Chinese and Filipino and Vietnamese and Korean and Japanese ethnicities. Cancer J Clin 2007; 57:190-205. doi.10.3322/canjclin.57.4.190

2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer 1975-2000 featuring the uses of surveillance data for cancer prevention and control. J National Cancer Inst 2003; 95:1276-99. doi.10.1093/jnci/djg040

3. Carini F, Mazzola M, Rappa F, Jurjus A, Geagea AG, Al Kattar S, et al. Colorectal carcinogenesis role of oxidative stress and antioxidants. Anticancer Res2017; 37:4759-66. doi.10.21873/anticanres.11882

4. Curtin JC. Novel drug discovery opportunities for colorectal cancer. Exp Opin Drug Dis2013; 8:1153-64. doi.10.1517/17460441.2013.807249

5. Berrino F, Krogh V, Riboli E. Epidemiology studies on diet and cancer. Tumori J 2003; 89:581-5. doi.10.1177/030089160308900601

6. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among Women. New Eng J Med 1990; 323:1664-72. doi.10.1056/NEJM199012133232404

7. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360:861-8. doi.10.1016/S0140-6736(02)09958-0

8. Manerio E, Rodas VL, Costas E, Hernandez JM. Shellfish consumption a major risk factor for colorectal cancer. Med Hyp 2008;70:409-12. doi.10.1016/j.mehy.2007.03.041

9. Kelsall HL, Baglietto L, Muller D, Haydon AM, English DR, Giles GG. The effect of socioeconomic status on survival from colorectal cancer in the Melbourne collaborative cohort study.Soc Sci Medi2009; 68:290-7. doi.10.1016/j.socscimed.2008.09.070

10. Antelo M, Castells A. Family history of colorectal cancer a new survival predictor of colon cancer? Gastroenterology 2009; 136:357-9. doi.10.1053/j.gastro.2008.11.059

11. Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Brit J Pharmacol 2009; 158:610-20. doi.10.1111/j.1476-5381.2009.00341.x

12. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5‐fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol 1980; 104:309-19. doi.10.1002/jcp.1041040305

13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximabmonotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. New Eng J Med2004; 351:337-45. doi.10.1056/NEJMoa033025

14. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene bax confers selective advantage during tumor clonal evolution. Proce National Acad Sci2000; 97:10872-7. doi.10.1073/pnas.190210897

15. Porter AG, Janicke RU. Emerging roles of caspase3 in apoptosis. Cell Death Dif1999; 699.

16. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, et al. Inhibition of Wnt signaling pathway decreases chemotherapy resistant side population colon cancer cells. Anticancer Res2010; 30:2041-8.

17. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR. New Eng J Med2010; 362:2380-8. doi.10.1056/NEJMoa0909530

18. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspase3 generated fragment of gelsolin effector of morphological change in apoptosis. Science 1997; 278:294-8. doi.10.1126/science.278.5336.294

19. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1 a human protein homologous to elegans CED4 participates in cytochrome dependent activation of caspase3. Cell 1997; 90:405-13. doi.10.1016/S0092-8674(00)80501-2

20. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of bax from the cytosol to mitochondria during apoptosis. J Cell Biol1997; 139:1281-92. doi. 10.1083/jcb.139.5.1281

21. Yin C, Knudson CM, Korsmeyer SJ, Vandyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385:637. doi.10.1038/385637a0

22. Riahichebbi I, Souid S, Othman H, Haoues M, Karoui H, Morel A, et al. The phenolic compound kaempferol overcomes 5fluorouracil resistance in human resistant LS174 colon cancer cells. Sci Rep2019; 9:195. doi.10.1038/s41598-018-36808-z

23. Longley DB, Harkin DP, Johnston PG. 5Fluorouracil mechanisms of action and clinical strategies. Nature Rev Cancer 2003; 3:330-8.

24. Riccivitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon cancer initiating cells. Nature 2007;445:111. doi.10.1038/nature05384

25. Oconnell MJ. A phase III trial of 5fluorouracil and leucovorin in the treatment of advanced colorectal cancer a mayo clinic north central cancer treatment group study. Cancer 1989;63:1026-30.

26. Steinmetz KA, Potter JD. Vegetables fruit and cancer. Epidemiol Cancer Caus Cont 1991;2:325-57. doi.10.1007/BF00051672

27. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5FU chemotherapy. Pharmacogenom J 2001; 1:65-70.

28. Jabboury K, Holmes FA, Hortobagyi G. 5fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer1989;64:793-7. doi.10.1002/1097-0143

29. 29 Arbuck SG. Overview of clinical trials using 5fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;63:1036-44. doi.10.1002/1097-0142

30. Ilghami R, Barzegari A, Mashayekhi MR, Letourneur D, Crepin M, Pavon G. The conundrum of dietary antioxidants in cancer chemotherapy. Nut Rev 2019;2:123-7. doi. 10.1093/nutrit/nuz027